Business
Brilinta met primary endpoint in stroke trial
Brilinta met primary endpoint in stroke trial.
About this update from Astrazeneca Plc
[{"type":"text","content":"\n \nRNS Number : 9331A AstraZeneca PLC 27 January 2020 \n\n27 January 2020 07:00 GMT\n \nBrilinta met primary endpoint in Phase III THALES trial in stroke\n \nBrilinta reduced the risk of the composite of stroke and death\nafter an acute ischaemic stroke or transient ischaemic attack\n \nHigh-level results from the Phase III THALES trial showed AstraZeneca's Brilinta (ticagrelor) 90mg used twice daily and taken with aspirin for 30 days, reached a statistically significant and clinically meaningful reduction in the risk of the primary composite endpoint of stroke and death, compared to aspirin alone.\n \nTHALES was conducted in over 11,000 patients who had a minor acute ischaemic stroke or high-risk transient ischaemic attack (TIA) in the 24 hours prior to treatment initiation. The preliminary safety findings in the THALES trial were consistent with the known profile of Brilinta, with an increased bleeding rate in the treatment arm.\n \nMene Pangalos, Executive Vice President, BioPharmaceuticals R&D, said: \"Results of the Phase III THALES trial showed Brilinta, in combination with aspirin, improved outcomes in patients who had experienced a minor acute ischaemic stroke or high-risk transient ischaemic attack. We look forward to sharing the detailed results with health authorities.\"\n \nDr. Clay Johnston, lead investigator for the THALES trial and Dean of the Dell Medical School at The University of Texas at Austin, US, said: \"The risk of having a subsequent stroke is highest in the first few days and weeks after a minor acute ischaemic stroke or high-risk transient ischaemic attack. While an expected increase in bleeding was observed, the findings from THALES showed that Brilinta, in combination with aspirin, reduced the risk of potentially devastating events in this crucial time.\"\n \nThe full THALES trial results will be presented at a forthcoming medical meeting.\n \nBrilinta is approved in more than 110 countries for the treatment of acute coronary syndrome (ACS) and in more than 70 countries for the secondary prevention of cardiovascular (CV) events among high-risk patients who have experienced a heart attack.\n \nStroke\nStroke is the second leading cause of death worldwide, with 6.2 million stroke-related deaths in 2017, from which 2.7 million were due t...